EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Can Patient Characteristics and Pre-Treatment MRI Features Predict Survival After Stereotactic Ablative Radiotherapy (SABR) Treatment in Hepatocellular Carcinoma (HCC): Preliminary Assessment

Rachel Gravell, Russell Frood iD, Anna Littlejohns, Nathalie Casanova, Rebecca Goody iD, Christine Podesta, Raneem Albazaz, Andrew Scarsbrook iD

Current Oncology · 2024

DOI: 10.3390/curroncol31100474 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Rachel Gravell und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, UK. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Radiosurgery, Magnetic Resonance Imaging. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Academic Clinical Fellowship, Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The study purpose was to develop a machine learning (ML)-based predictive model for event-free survival (EFS) in patients with hepatocellular carcinoma (HCC) undergoing stereotactic ablative radiotherapy (SABR).

Methods

Patients receiving SABR for HCC at a single institution, between 2017 and 2020, were included in the study. They were split into training and test (85%:15%) cohorts. Events of interest were HCC recurrence or death. Three ML models were trained, the features were selected, and the hyperparameters were tuned. The performance was measured using Harrell’s C index with the best-performing model being tested on the unseen cohort.

Results

Overall, 41 patients were included (training = 34, test = 7) and 64 lesions were analysed (training = 50, test = 14), resulting in 30 events (60% rate) in the training set (death = 6, recurrence = 24) and 8 events (57% rate) in the test set (death = 5, recurrence = 3). A Cox regression model, using age at treatment, albumin, and intra-lesional fat identified through MRI as variables, had the best performance with a mean training score of 0.78 (standard deviation (SD) 0.02), a mean validation of 0.78 (SD 0.18), and a test score of 0.94.

Conclusions

Predicting the outcomes in patients with HCC, following SABR, using a novel model is feasible and warrants further evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsRadiosurgeryMagnetic Resonance ImagingHumansMaleFemaleAgedMiddle AgedMachine LearningAged, 80 and over

Stichwörter der Autor:innen

hepatocellular carcinomamachine learningmagnetic resonance imagingradiotherapystereotactic techniques

Autor:innen und Institutionen

  • Department of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, UK.
  • Leeds Institute of Medical Research, Faculty of Medicine and Health, University of Leeds, Leeds LS2 9JT, UK.
  • Department of Oncology, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, UK.

ORCID-Profile: Russell Frood, Rebecca Goody, Andrew Scarsbrook

Förderung

  • NIHR Academic Clinical Fellowship
  • Cancer Research UK

Zitieren

APA

Gravell, R., Frood, R., Littlejohns, A., Casanova, N., Goody, R., Podesta, C., Albazaz, R., & Scarsbrook, A. (2024). Can Patient Characteristics and Pre-Treatment MRI Features Predict Survival After Stereotactic Ablative Radiotherapy (SABR) Treatment in Hepatocellular Carcinoma (HCC): Preliminary Assessment. Current Oncology. https://doi.org/10.3390/curroncol31100474

Vancouver

Gravell R, Frood R, Littlejohns A, Casanova N, Goody R, Podesta C, et al. Can Patient Characteristics and Pre-Treatment MRI Features Predict Survival After Stereotactic Ablative Radiotherapy (SABR) Treatment in Hepatocellular Carcinoma (HCC): Preliminary Assessment. Current Oncology. 2024. doi:10.3390/curroncol31100474

BibTeX
@article{Gravell2024,
  author = {Gravell, Rachel and Frood, Russell and Littlejohns, Anna and Casanova, Nathalie and Goody, Rebecca and Podesta, Christine and Albazaz, Raneem and Scarsbrook, Andrew},
  title = {Can Patient Characteristics and Pre-Treatment MRI Features Predict Survival After Stereotactic Ablative Radiotherapy (SABR) Treatment in Hepatocellular Carcinoma (HCC): Preliminary Assessment},
  journal = {Current Oncology},
  year = {2024},
  doi = {10.3390/curroncol31100474}
}
Kostenlos starten →